Since our inception in 2012, Open Medicine Foundation (OMF) has raised over $35 million to fund open and collaborative research and improve health care for millions suffering from multi-system chronic, complex diseases (msCCD) such as Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME/CFS), Long COVID, Post-Treatment Lyme Disease, and Fibromyalgia. We have facilitated and funded the establishment of 6 research centers across the globe, in 4 countries and 3 continents, dedicated to diagnosing, treating, and ultimately preventing these related chronic, complex diseases.
Open Medicine Foundation is a US-based global nonprofit, with an affiliate organization in Canada (OMF Canada) and a foreign branch in Australia (OMF Australia Ltd). OMF Canada received Charity Status from the Canada Revenue Agency on June 6, 2019. We launched our relationship with the Collaborative Research Center at CHU Sainte-Justine /Université de Montréal on December 11, 2019.
Our 19 member Scientific Advisory Board is world renowned and includes two Nobel laureates and 6 National Academy of Sciences members.
Alain Moreau, PhD
Director
Clinical and scientific intervention studies
Ronald W. Davis, PhD
Director
Innovative, collaborative, multi-disciplinary research
Wenzhong Xiao, PhD
Co-Director
David Systrom, MD
Co-Director
Clinical and scientific mechanistic studies towards discovering new treatments
Jonas Bergquist, MD, PhD
Director
Research for biomarkers in body and brain
Chris Armstrong, PhD
Director
Precision personalized medicine research program
The six, OMF funded, ME / CFS Collaborative Research Centres have launched an international study of the possible conversion of COVID-19 patients to ME / CFS.
This study, which seeks to learn about the pathways involved in the development of ME / CFS, can lead to biomarkers, new treatments, and prevention strategies.
19 world-renowned scientists
2 Nobel laureates
6 National Academy
of Sciences members
Please help us expand our research efforts across the globe.
Every donation brings us closer to a fully funded research effort and the answers we all seek.
"Our donors want to stop millions from suffering and have come to expect research with impeccable credibility. The time is now to attract the kind of serious investment that will speed up our search for a cure and end these debilitating diseases."
*Qualified donees are as follows:
